ImageBiopsy Lab (IB Lab) has launched an artificial intelligence (AI)-powered diagnostic for radiological and orthopaedic foot measurements.
The Vienna-based company’s IB Lab FROG, which is CE marked under Europe’s revised Medical Device Regulation (MDR), uses deep learning to provide automated measurements on dorsal-plantar and lateral X-ray images – based on radiological and orthopaedic standards – that are intended to aid in foot condition assessment.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to the company, incidence of foot-related pathologies is on the rise and increases with age, and while accurate radiographic measurements are essential in assessing various foot conditions, there is currently no gold standard for such measurements. IB Lab FROG is positioned as a means of providing clinicians with the accurate, standardised data required for the diagnosis and management of foot pathologies.
After use, IB Lab FROG generates data reports that can be accessed through any certified medical DICOM viewer.
IB Lab CEO and co-founder Richard Ljuhar said: “IB Lab FROG surpasses currently available algorithms by offering a comprehensive set of 17 measurements across five use cases, transforming the way clinicians assess foot conditions.
“With standardised and quantifiable data, IB Lab FROG streamlines workflows and supports informed treatment decisions.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIB Labs’ other products include IB LAMA, an automated radiological image processing software for geometric length and angle measurements of the lower limb on full leg X-rays, which received 510(k) clearance from the US Food and Drug Administration (FDA) in June 2023.
GlobalData’s 2023 AI in Healthcare report forecasts that AI platforms across healthcare will reach a global valuation of $18.8bn by 2027.
According to GlobalData’s Market Size & Growth database, the global orthopaedic devices market was worth around $52.4bn in 2023. Growing at a CAGR of 2.8% annually, it will reach a valuation of around $70.4bn by 2033.
